The serum metabolome serves as a diagnostic biomarker and discriminates patients with melanoma from healthy individuals.

IF 10.6 1区医学 Q1 CELL BIOLOGY

Cell Reports Medicine Pub Date : 2025-08-19 Epub Date: 2025-08-11 DOI:10.1016/j.xcrm.2025.102283

Yasser Morsy, Barbara Hubeli, Patrick Turko, Marjam Barysch, Julia M Martínez-Gómez, Nicola Zamboni, Gerhard Rogler, Reinhard Dummer, Mitchell P Levesque, Michael Scharl

{"title":"The serum metabolome serves as a diagnostic biomarker and discriminates patients with melanoma from healthy individuals.","authors":"Yasser Morsy, Barbara Hubeli, Patrick Turko, Marjam Barysch, Julia M Martínez-Gómez, Nicola Zamboni, Gerhard Rogler, Reinhard Dummer, Mitchell P Levesque, Michael Scharl","doi":"10.1016/j.xcrm.2025.102283","DOIUrl":null,"url":null,"abstract":"<p><p>Melanoma is a deadly cancer with increasing incidence and mortality rates, and biomarkers for diagnosis are urgently needed. The impact of the microbiome, genetic factors, and immunologic markers on disease outcomes is described, but a comprehensive serum metabolome profiling is missing. The serum metabolome of patients with melanoma might be valuable to identify potential biomarkers. We present an untargeted metabolomics analysis in an exploratory cohort (87 patients with melanoma), an independent validation cohort (37 additional patients with melanoma featuring late-stage tumors), and 18 healthy control individuals, revealing striking differences. We identify and validate six serum metabolites that can predict the diagnosis of melanoma with an area under the curve (AUC) >0.9544 in advanced-stage melanoma. The AUC of our lead biomarker, muramic acid, is 0.964, 0.908, and 0.9936 in patients with stage I (n = 22), stage II (n = 67), and advanced melanoma (n = 86), respectively. In summary, we identify potentially very powerful diagnostic biomarkers for clinical practice.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102283"},"PeriodicalIF":10.6000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432359/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xcrm.2025.102283","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Melanoma is a deadly cancer with increasing incidence and mortality rates, and biomarkers for diagnosis are urgently needed. The impact of the microbiome, genetic factors, and immunologic markers on disease outcomes is described, but a comprehensive serum metabolome profiling is missing. The serum metabolome of patients with melanoma might be valuable to identify potential biomarkers. We present an untargeted metabolomics analysis in an exploratory cohort (87 patients with melanoma), an independent validation cohort (37 additional patients with melanoma featuring late-stage tumors), and 18 healthy control individuals, revealing striking differences. We identify and validate six serum metabolites that can predict the diagnosis of melanoma with an area under the curve (AUC) >0.9544 in advanced-stage melanoma. The AUC of our lead biomarker, muramic acid, is 0.964, 0.908, and 0.9936 in patients with stage I (n = 22), stage II (n = 67), and advanced melanoma (n = 86), respectively. In summary, we identify potentially very powerful diagnostic biomarkers for clinical practice.

查看原文本刊更多论文

血清代谢组作为一种诊断性生物标志物，可将黑色素瘤患者与健康个体区分开来。

黑色素瘤是一种发病率和死亡率不断上升的致命癌症，迫切需要用于诊断的生物标志物。微生物组、遗传因素和免疫标记物对疾病结果的影响已被描述，但缺乏全面的血清代谢组谱分析。黑色素瘤患者的血清代谢组可能对识别潜在的生物标志物有价值。我们对一个探索性队列（87名黑色素瘤患者）、一个独立验证队列（37名晚期黑色素瘤患者）和18名健康对照个体进行了非靶向代谢组学分析，揭示了显著的差异。我们鉴定并验证了六种血清代谢物，这些代谢物可以预测晚期黑色素瘤的诊断，曲线下面积（AUC）为>0.9544。在I期（n = 22）、II期（n = 67）和晚期黑色素瘤（n = 86）患者中，我们的主要生物标志物瘤酸的AUC分别为0.964、0.908和0.9936。总之，我们为临床实践确定了潜在的非常强大的诊断生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell Reports Medicine Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

15.00

自引率

1.40%

发文量

231

审稿时长

40 days

期刊介绍： Cell Reports Medicine is an esteemed open-access journal by Cell Press that publishes groundbreaking research in translational and clinical biomedical sciences, influencing human health and medicine. Our journal ensures wide visibility and accessibility, reaching scientists and clinicians across various medical disciplines. We publish original research that spans from intriguing human biology concepts to all aspects of clinical work. We encourage submissions that introduce innovative ideas, forging new paths in clinical research and practice. We also welcome studies that provide vital information, enhancing our understanding of current standards of care in diagnosis, treatment, and prognosis. This encompasses translational studies, clinical trials (including long-term follow-ups), genomics, biomarker discovery, and technological advancements that contribute to diagnostics, treatment, and healthcare. Additionally, studies based on vertebrate model organisms are within the scope of the journal, as long as they directly relate to human health and disease.